

AOD-9604

HGH Fragment 177-191 | Lipolytic Peptide | Selective Beta-3 Adrenergic Activity

COMPOUND OVERVIEW

AOD-9604 is a truncated C-terminal fragment of human growth hormone, comprising amino acids 177-191. It retains the lipolytic properties of the full HGH molecule while lacking the domain responsible for insulin-like activity, producing selective adipose tissue effects in research models without glycaemic confounders of full-length HGH.

MECHANISM OF ACTION

AOD-9604 targets beta-3 adrenergic receptors on adipocytes, stimulating lipolysis and inhibiting lipogenesis. Unlike full-length HGH, it does not significantly affect IGF-1 levels or insulin sensitivity in studied models, making it useful for isolating fat metabolism pathways independently of anabolic or glycaemic variables.

RESEARCH APPLICATIONS

- Selective lipolysis and adipocyte receptor pharmacology
- Lipogenesis inhibition pathway studies
- Comparative metabolic research against full-length HGH
- Obesity model research requiring metabolic specificity

EVIDENCE STATUS & KNOWN LIMITATIONS

Evidence Status: AOD-9604 completed Phase IIb clinical trials for obesity treatment. It did not achieve primary endpoints at studied doses in human trials. Preclinical data supports lipolytic activity in rodent models; direct human efficacy is not established. Researchers should review published trial literature before experimental design.

ANALYTICAL & STORAGE DATA

PURITY	>99.5% by HPLC/MS	PHYSICAL FORM	Lyophilised White Powder
STORAGE	2-8 C. Protect from light.	ORIGIN	HGH Amino Acids 177-191
RECONSTITUTION	Bacteriostatic Water (USP)	BATCH DOCS	Available on Request

RECONSTITUTION NOTE

Introduce reconstitution solvent slowly against the interior vial wall. Allow natural dissolution without agitation. Solution should be clear and colourless. Store at 2-8C post-reconstitution.

REGULATORY CLASSIFICATION: All BioUnfolding compounds are strictly intended for laboratory evaluation and in-vitro analysis. These materials are not intended for human consumption, veterinary use, or therapeutic application. Researchers are solely responsible for compliance with applicable local regulations including SAHPRA guidelines.

REQUEST BATCH DOCUMENTATION

WhatsApp: +27 68 321 3641 | www.biounfolding.co.za | Cape Town, South Africa